絞り込み

16644

広告

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.

著者 Coleman R , Finkelstein DM , Barrios C , Martin M , Iwata H , Hegg R , Glaspy J , Periañez AM , Tonkin K , Deleu I , Sohn J , Crown J , Delaloge S , Dai T , Zhou Y , Jandial D , Chan A
Lancet Oncol.2019 Dec 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Medical

Miscellaneous

Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would increase bone metastasis-free survival in women with breast cancer.
PMID: 31806543 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード